ITOS — iTeos Therapeutics Share News
0.000.00%
Last trade - 00:00- $448.68m
- -$66.75m
- $35.00m
Brief: Iteos Promotes Yvonne Mcgrath To Chief Scientific Officer
U.S. STOCKS ON THE MOVE-Tesla, Container Store, Apple
U.S. STOCKS ON THE MOVE-Tesla, Armstrong Flooring, Immix Biopharma, BlueCity
U.S. STOCKS ON THE MOVE-Tesla, Armstrong Flooring, Carnival Corp, BlueCity
iTeos Therapeutics leaps as set to join S&P SmallCap index
Brief: Iteos Announces New Data For Its Anti-Tigit Antibody, EOS-448
Iteos Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Iteos Therapeutics Posts Quarterly EPS Of $1.86
Iteos Therapeutics Inc expected to post earnings of $4.95 a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Doximity, Roblox, Talos Energy
Iteos Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: iTeos Reports Q2 Loss Per Share Of $0.75
Iteos Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: iTeos Therapeutics's Unit Got Upfront Payment Of $625 Mln From Glaxosmithkline Intellectual Property Limited
iTeos Therapeutics rises on cancer treatment tie-up with GSK
GSK, iTeos to develop cancer drug in up to $2 bln deal (updated)
GSK ties up with iTeos to develop cancer treatment
Brief: GSK, Iteos Collaborate For EOS-448, Iteo To Get $625 Mln Upfront Payment
Brief: Iteos Therapeutics Announces New Phase 1/2A Data Indicating Antitumor Activity Of Inupadenant, Its Adenosine A2a Receptor Antagonist, At Asco 2021